News Center

ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

ACELYRIN, INC. Announces Pricing of Upsized Initial Public Offering

ACELYRIN, INC. Announces Launch of IPO Roadshow

ACELYRIN, INC. Announces Magnitude of Clinical Responses with Izokibep in Psoriatic Arthritis Continues to Improve with Longer Duration of Therapy

Henry Gosebruch, Former AbbVie EVP and Chief Strategy Officer, Joins ACELYRIN, INC. Board of Directors

ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa

ACELYRIN, INC. Furthers Leadership Position in Immunology with Transformative Acquisition of ValenzaBio

ACELYRIN, INC. to Accelerate Development of Izokibep in Hidradenitis Suppurativa